Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies

摘要 请求支持题为抗体作为药物的抗体：新的地平线的Keystone研讨会 工程抗体的治疗应用，由Christian Klein博士、Mark S.Cragg博士和Germaine博士组织 啊哈。大会将于2019年4月7日至11日在科罗拉多州布雷肯里奇举行。 在过去的二十年里，重组抗体已经被建立在临床实践中，用于治疗 治疗从癌症到自身免疫和传染病的各种疾病。而第一批被批准的 抗体是天然的免疫球蛋白抗体，近年来在该领域得到了迅速的发展和治疗 临床前和临床开发中的抗体现在包括许多非规范形式，包括Fc- 工程抗体、抗体药物结合物、双特异性抗体和抗体样支架。这 Keystone研讨会旨在汇聚抗体疗法、工程学和 产业界和学术界的行动机制，讨论和审查该领域的最新技术和 讨论他们未来的潜力。会议将促进不同工程之间的相互促进。 来自不同治疗领域的技术和科学家。这个会议还可以帮助发起 合作开发最先进的抗体疗法，目的是改善治疗 病人的选择。对于实习生和职业生涯早期的研究人员来说，这次会议提供了一个获得 深入了解治疗性抗体的各个方面，面对面地讨论他们的项目和想法 该领域的专家。这次会议的一个独特组成部分，使其有别于其他更商业化的会议 外地会议的一个重要特点是，本次会议将包括介绍和讨论新颖/未公布的数据。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies, organized by Drs. Christian Klein, Mark S. Cragg and Germaine Fuh. The conference will be held in Breckenridge, Colorado from April 7-11, 2019. Over the last twenty years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.